Brand-name Latuda (lurasidone) is protected by a patent until at least July 2018. This means that generic versions of this antipsychotic drug cannot be sold until this patent expires, provided there are no other outstanding patents or unresolved lawsuits. Once this patent expires, several companies could start making generic versions of Latuda.
Latuda® (lurasidone hydrochloride) is a prescription antipsychotic medication. It is approved for treating schizophrenia and bipolar depression.
Latuda is manufactured by Sunovion Pharmaceuticals, Inc. It is currently under the protection of a patent that prevents any generic versions from being manufactured in the United States.
The first patent for Latuda currently expires in July 2018. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to extend or shorten the exclusivity period. This could include such things as lawsuits or other patents for Latuda uses. Once the patent expires, there may be several companies that manufacture a generic Latuda drug.
No -- lurasidone is the active ingredient in Latuda. but is not a generic version of it. What can be confusing is that the active ingredient of any drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.